Drug Profile
Research programme: wnt signalling pathway inhibitors - Bayer HealthCare Pharmaceuticals/OncoMed
Latest Information Update: 29 Apr 2019
Price :
$50
*
At a glance
- Originator Bayer Schering Pharma; OncoMed Pharmaceuticals
- Developer Bayer HealthCare Pharmaceuticals; OncoMed Pharmaceuticals
- Class Antibodies; Proteins; Small molecules
- Mechanism of Action Stem cell inhibitors; Wnt signalling pathway inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 24 Apr 2019 OncoMed Pharmaceuticals has been acquired by Mereo BioPharma
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Germany
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA